Haemodynamic effects of intravenous human calcitonin-gene-related peptide in man

Colin Howden, C. Logue, K. Gavin, L. Collie, P. C. Rubin

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

1. The effects of intravenous bolus doses of human calcitonin-gene-related peptide (hCGRP) were studied in ten healthy male volunteers. 2.5, 10 and 25 μg of the hCGRP and placebo were administered to each subject in a randomized double-blind study. 2. hCGRP had no effect on systolic or diastolic blood pressure in the supine or standing position. 3. hCGRP increased supine and standing heart rate. Both the extent and duration of the tachycardia were dose related. 4. Plasma noradrenaline levels were transiently increased after 10 and 25 μg of hCGRP. 5. All subjects displayed marked facial flushing after the two higher doses of hCGRP. 6. We conclude that systemic administration of hCGRP produces tachycardia and stimulation of the sympathetic nervous system in the absence of any change in blood pressure.

Original languageEnglish (US)
Pages (from-to)413-418
Number of pages6
JournalClinical Science
Volume74
Issue number4
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Calcitonin Gene-Related Peptide
Hemodynamics
Blood Pressure
Tachycardia
Supine Position
Sympathetic Nervous System
Posture
Double-Blind Method
Norepinephrine
Healthy Volunteers
Heart Rate
Placebos

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Haemodynamic effects of intravenous human calcitonin-gene-related peptide in man. / Howden, Colin; Logue, C.; Gavin, K.; Collie, L.; Rubin, P. C.

In: Clinical Science, Vol. 74, No. 4, 01.01.1988, p. 413-418.

Research output: Contribution to journalArticle

Howden, Colin ; Logue, C. ; Gavin, K. ; Collie, L. ; Rubin, P. C. / Haemodynamic effects of intravenous human calcitonin-gene-related peptide in man. In: Clinical Science. 1988 ; Vol. 74, No. 4. pp. 413-418.
@article{85c59c2ee7554eb497cbf3c1fcd37b57,
title = "Haemodynamic effects of intravenous human calcitonin-gene-related peptide in man",
abstract = "1. The effects of intravenous bolus doses of human calcitonin-gene-related peptide (hCGRP) were studied in ten healthy male volunteers. 2.5, 10 and 25 μg of the hCGRP and placebo were administered to each subject in a randomized double-blind study. 2. hCGRP had no effect on systolic or diastolic blood pressure in the supine or standing position. 3. hCGRP increased supine and standing heart rate. Both the extent and duration of the tachycardia were dose related. 4. Plasma noradrenaline levels were transiently increased after 10 and 25 μg of hCGRP. 5. All subjects displayed marked facial flushing after the two higher doses of hCGRP. 6. We conclude that systemic administration of hCGRP produces tachycardia and stimulation of the sympathetic nervous system in the absence of any change in blood pressure.",
author = "Colin Howden and C. Logue and K. Gavin and L. Collie and Rubin, {P. C.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1042/cs0740413",
language = "English (US)",
volume = "74",
pages = "413--418",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Haemodynamic effects of intravenous human calcitonin-gene-related peptide in man

AU - Howden, Colin

AU - Logue, C.

AU - Gavin, K.

AU - Collie, L.

AU - Rubin, P. C.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - 1. The effects of intravenous bolus doses of human calcitonin-gene-related peptide (hCGRP) were studied in ten healthy male volunteers. 2.5, 10 and 25 μg of the hCGRP and placebo were administered to each subject in a randomized double-blind study. 2. hCGRP had no effect on systolic or diastolic blood pressure in the supine or standing position. 3. hCGRP increased supine and standing heart rate. Both the extent and duration of the tachycardia were dose related. 4. Plasma noradrenaline levels were transiently increased after 10 and 25 μg of hCGRP. 5. All subjects displayed marked facial flushing after the two higher doses of hCGRP. 6. We conclude that systemic administration of hCGRP produces tachycardia and stimulation of the sympathetic nervous system in the absence of any change in blood pressure.

AB - 1. The effects of intravenous bolus doses of human calcitonin-gene-related peptide (hCGRP) were studied in ten healthy male volunteers. 2.5, 10 and 25 μg of the hCGRP and placebo were administered to each subject in a randomized double-blind study. 2. hCGRP had no effect on systolic or diastolic blood pressure in the supine or standing position. 3. hCGRP increased supine and standing heart rate. Both the extent and duration of the tachycardia were dose related. 4. Plasma noradrenaline levels were transiently increased after 10 and 25 μg of hCGRP. 5. All subjects displayed marked facial flushing after the two higher doses of hCGRP. 6. We conclude that systemic administration of hCGRP produces tachycardia and stimulation of the sympathetic nervous system in the absence of any change in blood pressure.

UR - http://www.scopus.com/inward/record.url?scp=0023874446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023874446&partnerID=8YFLogxK

U2 - 10.1042/cs0740413

DO - 10.1042/cs0740413

M3 - Article

VL - 74

SP - 413

EP - 418

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 4

ER -